An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients with Chronic Hepatitis B Receiving Pegylated Interferon-Alpha 2a (Pegasys)

Young Eun Chon, Dong Joon Kim, Sang Gyune Kim, In Hee Kim, Si Hyun Bae, Seong Gyu Hwang, Jeong Heo, Jeong Won Jang, Byung Seok Lee, Hyung Joon Kim, Dae Won Jun, Kang Mo Kim, Woo Jin Chung, Moon Seok Choi, Jae Young Jang, Hyung Joon Yim, Won Young Tak, Ki Tae Yoon, Jun Yong Park, Kwang Hyub HanKi Tae Suk, Hyun Woong Lee, Byoung Kuk Jang, Sang Hoon Ahn

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Currently, limited data are available regarding the efficacy and safety of pegylated interferon alpha-2a (PEG-IFN α-2a) in Korean patients with chronic hepatitis B (CHB), in whom hepatitis B virus (HBV) genotype C is the most common type. We collected data from 439 patients (HBeAg positive, n;=;349; HBeAg negative, n;=;90) with CHB who were treated with PEG-IFN α-2a as a first-line therapy from 18 institutions. Treatment responses at the end of treatment (ET) and at 6 months posttreatment (PT6) were compared between the patients who were treated for 24 weeks versus 48 weeks, and adverse events (AEs) were evaluated. In HBeAg-positive patients, those who received PEG-IFN α-2a for 48 weeks showed significantly higher HBV DNA suppression (HBV DNA;<;2000;IU/mL) than those who were treated for 24 weeks (48 weeks vs 24 weeks; at ET, 44.4% vs 36.7%, P;=;0.035; at PT6, 35.9% vs 13.3%, P;=;0.035). The HBeAg seroconversion rate at ET was 18.1% in 48-week treatment group, which is significantly higher than the 2.2% (P;<;0.001) that was seen in 24-week treatment group. This finding also continued at PT6 (29.0% vs 10.0%, P;<;0.001). Following 48 weeks of treatment in HBeAg-negative patients, HBV DNA suppression at ET was higher than in HBeAg-positive patients (87.8% vs 44.4%). AEs were typical of those associated with PEG-IFN α-2a. In naïve Korean HBeAg-positive CHB patients treated with PEG-IFN α-2a, higher rates of HBV DNA suppression and HBeAg seroconversion were achieved in the 48-week treatment group than in the 24-week treatment group without additional risk of AEs.

Original languageEnglish
Article numbere3026
JournalMedicine (United States)
Volume95
Issue number14
DOIs
Publication statusPublished - 2016 Apr 1

Fingerprint

Chronic Hepatitis B
Multicenter Studies
Antiviral Agents
Hepatitis B e Antigens
Cohort Studies
Safety
Hepatitis B virus
Therapeutics
DNA
peginterferon alfa-2a
Genotype

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Chon, Young Eun ; Kim, Dong Joon ; Kim, Sang Gyune ; Kim, In Hee ; Bae, Si Hyun ; Hwang, Seong Gyu ; Heo, Jeong ; Jang, Jeong Won ; Lee, Byung Seok ; Kim, Hyung Joon ; Jun, Dae Won ; Kim, Kang Mo ; Chung, Woo Jin ; Choi, Moon Seok ; Jang, Jae Young ; Yim, Hyung Joon ; Tak, Won Young ; Yoon, Ki Tae ; Park, Jun Yong ; Han, Kwang Hyub ; Suk, Ki Tae ; Lee, Hyun Woong ; Jang, Byoung Kuk ; Ahn, Sang Hoon. / An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients with Chronic Hepatitis B Receiving Pegylated Interferon-Alpha 2a (Pegasys). In: Medicine (United States). 2016 ; Vol. 95, No. 14.
@article{7374e92e29ab4ae1bbef5d67c6f29815,
title = "An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients with Chronic Hepatitis B Receiving Pegylated Interferon-Alpha 2a (Pegasys)",
abstract = "Currently, limited data are available regarding the efficacy and safety of pegylated interferon alpha-2a (PEG-IFN α-2a) in Korean patients with chronic hepatitis B (CHB), in whom hepatitis B virus (HBV) genotype C is the most common type. We collected data from 439 patients (HBeAg positive, n;=;349; HBeAg negative, n;=;90) with CHB who were treated with PEG-IFN α-2a as a first-line therapy from 18 institutions. Treatment responses at the end of treatment (ET) and at 6 months posttreatment (PT6) were compared between the patients who were treated for 24 weeks versus 48 weeks, and adverse events (AEs) were evaluated. In HBeAg-positive patients, those who received PEG-IFN α-2a for 48 weeks showed significantly higher HBV DNA suppression (HBV DNA;<;2000;IU/mL) than those who were treated for 24 weeks (48 weeks vs 24 weeks; at ET, 44.4{\%} vs 36.7{\%}, P;=;0.035; at PT6, 35.9{\%} vs 13.3{\%}, P;=;0.035). The HBeAg seroconversion rate at ET was 18.1{\%} in 48-week treatment group, which is significantly higher than the 2.2{\%} (P;<;0.001) that was seen in 24-week treatment group. This finding also continued at PT6 (29.0{\%} vs 10.0{\%}, P;<;0.001). Following 48 weeks of treatment in HBeAg-negative patients, HBV DNA suppression at ET was higher than in HBeAg-positive patients (87.8{\%} vs 44.4{\%}). AEs were typical of those associated with PEG-IFN α-2a. In na{\"i}ve Korean HBeAg-positive CHB patients treated with PEG-IFN α-2a, higher rates of HBV DNA suppression and HBeAg seroconversion were achieved in the 48-week treatment group than in the 24-week treatment group without additional risk of AEs.",
author = "Chon, {Young Eun} and Kim, {Dong Joon} and Kim, {Sang Gyune} and Kim, {In Hee} and Bae, {Si Hyun} and Hwang, {Seong Gyu} and Jeong Heo and Jang, {Jeong Won} and Lee, {Byung Seok} and Kim, {Hyung Joon} and Jun, {Dae Won} and Kim, {Kang Mo} and Chung, {Woo Jin} and Choi, {Moon Seok} and Jang, {Jae Young} and Yim, {Hyung Joon} and Tak, {Won Young} and Yoon, {Ki Tae} and Park, {Jun Yong} and Han, {Kwang Hyub} and Suk, {Ki Tae} and Lee, {Hyun Woong} and Jang, {Byoung Kuk} and Ahn, {Sang Hoon}",
year = "2016",
month = "4",
day = "1",
doi = "10.1097/MD.0000000000003026",
language = "English",
volume = "95",
journal = "Medicine (United States)",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "14",

}

Chon, YE, Kim, DJ, Kim, SG, Kim, IH, Bae, SH, Hwang, SG, Heo, J, Jang, JW, Lee, BS, Kim, HJ, Jun, DW, Kim, KM, Chung, WJ, Choi, MS, Jang, JY, Yim, HJ, Tak, WY, Yoon, KT, Park, JY, Han, KH, Suk, KT, Lee, HW, Jang, BK & Ahn, SH 2016, 'An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients with Chronic Hepatitis B Receiving Pegylated Interferon-Alpha 2a (Pegasys)', Medicine (United States), vol. 95, no. 14, e3026. https://doi.org/10.1097/MD.0000000000003026

An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients with Chronic Hepatitis B Receiving Pegylated Interferon-Alpha 2a (Pegasys). / Chon, Young Eun; Kim, Dong Joon; Kim, Sang Gyune; Kim, In Hee; Bae, Si Hyun; Hwang, Seong Gyu; Heo, Jeong; Jang, Jeong Won; Lee, Byung Seok; Kim, Hyung Joon; Jun, Dae Won; Kim, Kang Mo; Chung, Woo Jin; Choi, Moon Seok; Jang, Jae Young; Yim, Hyung Joon; Tak, Won Young; Yoon, Ki Tae; Park, Jun Yong; Han, Kwang Hyub; Suk, Ki Tae; Lee, Hyun Woong; Jang, Byoung Kuk; Ahn, Sang Hoon.

In: Medicine (United States), Vol. 95, No. 14, e3026, 01.04.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients with Chronic Hepatitis B Receiving Pegylated Interferon-Alpha 2a (Pegasys)

AU - Chon, Young Eun

AU - Kim, Dong Joon

AU - Kim, Sang Gyune

AU - Kim, In Hee

AU - Bae, Si Hyun

AU - Hwang, Seong Gyu

AU - Heo, Jeong

AU - Jang, Jeong Won

AU - Lee, Byung Seok

AU - Kim, Hyung Joon

AU - Jun, Dae Won

AU - Kim, Kang Mo

AU - Chung, Woo Jin

AU - Choi, Moon Seok

AU - Jang, Jae Young

AU - Yim, Hyung Joon

AU - Tak, Won Young

AU - Yoon, Ki Tae

AU - Park, Jun Yong

AU - Han, Kwang Hyub

AU - Suk, Ki Tae

AU - Lee, Hyun Woong

AU - Jang, Byoung Kuk

AU - Ahn, Sang Hoon

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Currently, limited data are available regarding the efficacy and safety of pegylated interferon alpha-2a (PEG-IFN α-2a) in Korean patients with chronic hepatitis B (CHB), in whom hepatitis B virus (HBV) genotype C is the most common type. We collected data from 439 patients (HBeAg positive, n;=;349; HBeAg negative, n;=;90) with CHB who were treated with PEG-IFN α-2a as a first-line therapy from 18 institutions. Treatment responses at the end of treatment (ET) and at 6 months posttreatment (PT6) were compared between the patients who were treated for 24 weeks versus 48 weeks, and adverse events (AEs) were evaluated. In HBeAg-positive patients, those who received PEG-IFN α-2a for 48 weeks showed significantly higher HBV DNA suppression (HBV DNA;<;2000;IU/mL) than those who were treated for 24 weeks (48 weeks vs 24 weeks; at ET, 44.4% vs 36.7%, P;=;0.035; at PT6, 35.9% vs 13.3%, P;=;0.035). The HBeAg seroconversion rate at ET was 18.1% in 48-week treatment group, which is significantly higher than the 2.2% (P;<;0.001) that was seen in 24-week treatment group. This finding also continued at PT6 (29.0% vs 10.0%, P;<;0.001). Following 48 weeks of treatment in HBeAg-negative patients, HBV DNA suppression at ET was higher than in HBeAg-positive patients (87.8% vs 44.4%). AEs were typical of those associated with PEG-IFN α-2a. In naïve Korean HBeAg-positive CHB patients treated with PEG-IFN α-2a, higher rates of HBV DNA suppression and HBeAg seroconversion were achieved in the 48-week treatment group than in the 24-week treatment group without additional risk of AEs.

AB - Currently, limited data are available regarding the efficacy and safety of pegylated interferon alpha-2a (PEG-IFN α-2a) in Korean patients with chronic hepatitis B (CHB), in whom hepatitis B virus (HBV) genotype C is the most common type. We collected data from 439 patients (HBeAg positive, n;=;349; HBeAg negative, n;=;90) with CHB who were treated with PEG-IFN α-2a as a first-line therapy from 18 institutions. Treatment responses at the end of treatment (ET) and at 6 months posttreatment (PT6) were compared between the patients who were treated for 24 weeks versus 48 weeks, and adverse events (AEs) were evaluated. In HBeAg-positive patients, those who received PEG-IFN α-2a for 48 weeks showed significantly higher HBV DNA suppression (HBV DNA;<;2000;IU/mL) than those who were treated for 24 weeks (48 weeks vs 24 weeks; at ET, 44.4% vs 36.7%, P;=;0.035; at PT6, 35.9% vs 13.3%, P;=;0.035). The HBeAg seroconversion rate at ET was 18.1% in 48-week treatment group, which is significantly higher than the 2.2% (P;<;0.001) that was seen in 24-week treatment group. This finding also continued at PT6 (29.0% vs 10.0%, P;<;0.001). Following 48 weeks of treatment in HBeAg-negative patients, HBV DNA suppression at ET was higher than in HBeAg-positive patients (87.8% vs 44.4%). AEs were typical of those associated with PEG-IFN α-2a. In naïve Korean HBeAg-positive CHB patients treated with PEG-IFN α-2a, higher rates of HBV DNA suppression and HBeAg seroconversion were achieved in the 48-week treatment group than in the 24-week treatment group without additional risk of AEs.

UR - http://www.scopus.com/inward/record.url?scp=84964612656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964612656&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000003026

DO - 10.1097/MD.0000000000003026

M3 - Article

C2 - 27057828

AN - SCOPUS:84964612656

VL - 95

JO - Medicine (United States)

JF - Medicine (United States)

SN - 0025-7974

IS - 14

M1 - e3026

ER -